Mercy can now test for over 50 types of cancer before symptoms even appear. Get answers to frequently asked questions to see if this revolutionary new test is right for you.
The test, called Galleri®, is offered by a company called GRAIL. It received Food and Drug Administration Breakthrough Device designation in October 2021, fast-tracking its review for full FDA approval while additional data is gathered in large-scale clinical trials.
The Multi-Cancer Early Detection test detects more than 50 types of cancer signals, many of which are not commonly screened for today, through a simple blood sample. The MCED test doesn’t diagnose cancer and not all cancers may be detected in the blood.
The MCED test looks for signals present in the blood that may be associated with cancer at the time you give your blood sample. If a cancer signal is detected, the results can point to where in the body the cancer is coming from to help your health care provider guide the next steps.
The MCED test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. Complete our online screener to see if you’re eligible. The MCED test is intended to be used in addition to, and not replace, other cancer screening tests recommended by your health care provider.
Family history is only one of many risk factors associated with cancer development. Other risk factors include eating habits, lifestyle, living or working environments, genetics and many other factors. So you may still be a good candidate for the MCED test without a family history.
In a large-scale, clinical validation sub-study of Circulating Cell-free Genome Atlas, the MCED test detected more than 50 cancer types across all stages, including:
Adrenal Cortical Carcinoma
Ampulla of Vater
Bile Ducts, Distal
Bile Ducts, Intrahepatic
Bile Ducts, Perihilar
Colon and Rectum
Esophagus and Esophagogastric Junction
Gastrointestinal Stromal Tumor
Gestational Trophoblastic Neoplasms
Lymphoma (Hodgkin and Non-Hodgkin)
Melanoma of the Skin
Merkel Cell Carcinoma
Mesothelioma, Malignant Pleural
Nasal Cavity and Paranasal Sinuses
Neuroendocrine Tumors of the Appendix
Neuroendocrine Tumors of the Colon and Rectum
Neuroendocrine Tumors of the Pancreas
Oropharynx (HPV-Mediated, p16+)
Oropharynx (p16-) and Hypopharynx
Ovary, Fallopian Tube and Primary Peritoneum
Plasma Cell Myeloma and Plasma Cell Disorders
Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs
Soft Tissue Sarcoma of the Head and Neck
Soft Tissue Sarcoma of the Retroperitoneum
Soft Tissue Sarcoma of the Trunk and Extremities
Soft Tissue Sarcoma Unusual Histologies and Sites
Ureter, Renal Pelvis
Uterus, Carcinoma and Carcinosarcoma
Based on data from GRAIL’s studies, the MCED test has shown a low false-positive rate of 0.5% (detecting a cancer signal when no cancer is present). This means that in approximately 200 people tested, only one person would be expected to receive a false-positive result.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing.
You can complete our online screener to see if you’re eligible for the test. If you’re eligible, the Mercy care team will reach out with next steps.
The MCED test will be available in 11 Mercy labs located within our hospitals. The Mercy care team will work with you to schedule your appointment at the facility closest to you.
People 22 and older, but it will be especially recommended for adults with an elevated risk for cancer, such as those age 50 or above with select pre-existing conditions and/or family history.
If you request the test yourself using an online form, the Mercy care team will walk you through the process. A Mercy physician or provider can also refer you to the right Mercy care team.
Mercy’s price for the MCED test is $949.
If you’re at an elevated risk for cancer due to environmental or genetic factors and are unable to pay the total cost of the test, Mercy will work with you individually to assist in making this service accessible.
Currently, this test is not covered by insurance. The test is new to the market and represents a significant innovation in cancer screening.
You may be able to use pre-tax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the MCED test. Check with your FSA/HSA account administrator or insurance company to determine eligibility.
Because each insurance company creates its own criteria for coverage of tests, your Mercy care team will work with you and your insurance company to obtain coverage of further diagnostic testing.
No preparation or fasting is required for the Multi-Cancer Early Detection test.
Approximately 1.5 tablespoons (or about 20 ml) of blood in two tubes, typically from a vein in your arm.
It takes about two weeks after your lab visit to receive your test results from your Mercy care team who ordered your test.
This means that there is a suspicion of cancer but not a diagnosis of cancer. The Multi-Cancer Early Detection test can point to where in the body the cancer is coming from to help your Mercy care team guide next steps. Your Mercy care team will discuss appropriate follow-up testing to confirm if cancer is present.
This means that no cancer signal was found. However, not all cancers can be detected by the Multi-Cancer Early Detection test. Continue with all routine screening tests recommended by your care team. Missing routine screenings or ignoring symptoms can lead to a delayed diagnosis of cancer.
The MCED test looks for a common cancer signal across more than 50 types of cancer, and not all cancers may be detected in the blood. Recommended routine cancer screenings such as colonoscopy or mammograms are commonly used and have been shown to reduce cancer deaths. The MCED test is intended to be used in addition to, and not replace, these tests and can help maximize the benefits of early cancer detection. Missing recommended screenings or ignoring symptoms could lead to a delayed diagnosis of cancer. Ask your health care provider about what cancer screening tests are right for you.
The MCED test is a screening test that detects cancer signals in blood. When a signal is detected, the test also indicates where in the body the signal is coming from with high accuracy.
The MCED test isn’t a diagnostic test. Additional tests ordered by your Mercy care team are needed to confirm if cancer is present. These tests may include blood work or imaging.
The MCED test is looking for the presence of cancer at the time your blood sample is taken, but you may develop cancer in the future. The test doesn’t measure your risk of developing cancer in the future, and it does not detect all cancers.
If you receive a “cancer signal detected” result with the Multi-Cancer Early Detection test, but a follow-up diagnostic evaluation doesn’t confirm cancer, your Mercy care team will review the different recommendations with you.
Early detection saves lives. Mercy can test for 50 types of cancer before symptoms appear. See if you’re eligible.